Tarsus Pharmaceuticals Q3 net loss widens to $668.33 million
Bitget2026/11/03 21:17- Tarsus Pharmaceuticals’ third-quarter 2026 net loss widened year-over-year to $668.3 million.
- Net product sales rose approximately 64% year-over-year to $194.6 million, driven by higher volume and improved gross-to-net discounts.
- Acquired in-process research and development expenses totaled $632.2 million, related to the iRenix Medical and Alkeus Pharmaceuticals acquisitions.
- Topline results from Phase 2 trials of TP-04 for ocular rosacea and TP-05 for Lyme disease prevention are expected in first-half 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
